Bristol Myers Squibb | Pfizer – Atrial Fibrillation and Venous Thromboembolism – Request for Proposals
Academic Unit: Inquire with your unit
Memorial Deadline: Please contact RGCS
External Deadline: Wednesday 1st, September 2021
Pfizer and Bristol-Myers Squibb (BMS) are collaborating to provide grant support for continuing professional education in the areas of atrial fibrillation and venous thromboembolism. We are committed to supporting innovative, independent medical education for healthcare professionals. Grants via this collaboration will be funded by Pfizer, but reviewed and approved by both companies.
Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s GMG competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the specific RFP.
For all independent medical education grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct of the independent education program.
Applications will be accepted on rolling basis through September but reviewed based on the timelines below.
|Application Submitted by||Decision Notification Date||Anticipated Project Start Date|
|May 3, 2021||June 1, 2021||August 2021|
|July 1, 2021||August 1, 2021||October 2021|
|September 1, 2021||October 1, 2021||December 2021|